Acura Pharmaceuticals, Inc. (ACUR) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ACUR representa a Acura Pharmaceuticals, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Acura Pharmaceuticals, Inc. (ACUR) Resumen de Asistencia Médica y Tuberías
Acura Pharmaceuticals, Inc. is a drug delivery company focused on developing and commercializing technologies for safer medication use, particularly in pain management and nasal decongestion. Its product portfolio includes Oxaydo and Nexafed, with ongoing research into abuse-deterrent formulations and collaborative agreements for global market expansion.
Tesis de Inversión
Acura Pharmaceuticals, Inc. presents a focused investment opportunity within the specialty pharmaceutical sector. The company's commitment to developing abuse-deterrent formulations addresses a critical need in pain management. Key value drivers include the potential for increased adoption of Oxaydo and Nexafed products, coupled with successful development and commercialization of its pipeline products, including LTX-03. The company's gross margin of 94.2% indicates strong pricing power. However, the company's negative profit margin of -56.2% and negative free cash flow of $-0.00B highlight the need for improved financial performance. Upcoming catalysts include potential regulatory approvals for new formulations and expansion of existing product lines. Potential risks include competition from established pharmaceutical companies and challenges in securing additional funding for research and development.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Gross Margin of 94.2% indicates strong pricing power in its product offerings.
- Negative Profit Margin of -56.2% reflects ongoing investments in research and development and commercialization efforts.
- Free Cash Flow of $-0.00B indicates the company is currently reliant on external funding.
- Beta of -54.49 suggests the stock price is inversely correlated with the market.
- The company has six additional opioid products in various stages of formulation development, signaling future growth potential.
Competidores y Pares
Fortalezas
- Proprietary abuse-deterrent drug delivery technologies.
- Established partnerships with other pharmaceutical companies.
- Focus on a growing market segment (abuse-deterrent formulations).
- High gross margin (94.2%).
Debilidades
- Negative profit margin (-56.2%).
- Negative free cash flow.
- Small number of employees (9).
- Limited product portfolio.
Catalizadores
- Upcoming: Potential regulatory approval for new abuse-deterrent formulations.
- Upcoming: Expansion of existing product lines into new markets.
- Ongoing: Research and development of new drug delivery technologies.
- Ongoing: Strategic partnerships with other pharmaceutical companies.
- Ongoing: Efforts to increase market share for Oxaydo and Nexafed.
Riesgos
- Potential: Competition from larger pharmaceutical companies with greater resources.
- Potential: Regulatory changes impacting opioid prescriptions and abuse-deterrent formulations.
- Potential: Challenges in securing funding for research and development.
- Ongoing: Dependence on key partnerships for product development and commercialization.
- Ongoing: Limited liquidity due to trading on the OTC market.
Oportunidades de crecimiento
- Expansion of Oxaydo Market Share: Acura has the opportunity to increase the market share of Oxaydo, its abuse-deterrent opioid, by targeting specific patient populations and expanding its distribution network. The market for abuse-deterrent opioids is growing due to increasing awareness of opioid abuse and regulatory initiatives promoting safer pain management options. Success in this area could significantly boost revenue within the next 2-3 years.
- Commercialization of LTX-03: The successful development and commercialization of LTX-03, an immediate-release tablet utilizing LIMITx technology, represents a significant growth opportunity for Acura. This product aims to provide effective pain relief while minimizing the risk of abuse. Positive clinical trial results and regulatory approval could lead to substantial revenue generation within the next 3-5 years.
- Geographic Expansion: Acura can explore opportunities to expand its geographic reach by partnering with international distributors or establishing a direct presence in key markets. The global market for pain management and nasal decongestant products is substantial, and expanding into new regions could drive significant revenue growth over the next 5 years.
- Development of New Abuse-Deterrent Formulations: Acura's expertise in drug delivery technology positions it to develop new abuse-deterrent formulations for other commonly abused medications. This could involve partnering with other pharmaceutical companies or developing its own proprietary products. Successful development and commercialization of new formulations could create new revenue streams within the next 3-5 years.
- Strategic Partnerships and Acquisitions: Acura can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. This could involve acquiring companies with complementary technologies or products, or partnering with larger pharmaceutical companies to co-develop and commercialize new medications. Such partnerships could accelerate growth and diversify revenue streams over the next 2-5 years.
Oportunidades
- Expansion of Oxaydo market share.
- Commercialization of LTX-03.
- Geographic expansion.
- Development of new abuse-deterrent formulations.
Amenazas
- Competition from larger pharmaceutical companies.
- Regulatory changes impacting opioid prescriptions.
- Challenges in securing funding for research and development.
- Potential product liability claims.
Ventajas competitivas
- Proprietary drug delivery technologies that enhance medication safety.
- Patents protecting its formulations and technologies.
- Established partnerships with other pharmaceutical companies.
- Expertise in developing abuse-deterrent formulations.
Acerca de ACUR
Acura Pharmaceuticals, Inc., established in 1935 and headquartered in Palatine, Illinois, is dedicated to the research, development, and commercialization of pharmaceutical products designed to improve medication safety. The company's primary focus is on creating innovative drug delivery technologies that address the challenges associated with prescription drug abuse and misuse. Acura's product portfolio includes Oxaydo, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain. Additionally, the company offers Nexafed products, which are pseudoephedrine and acetaminophen tablets used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy medications. Acura Pharmaceuticals operates through strategic collaboration and license agreements with companies like Egalet US, Inc., Egalet Ltd., and Abuse Deterrent Pharma, LLC. These partnerships enable Acura to manufacture, commercialize, and further develop its product offerings, including LTX-03, an immediate-release tablet utilizing LIMITx technology. With a lean team of 9 employees, Acura Pharmaceuticals continues to innovate in the drug delivery space, aiming to provide safer and more effective medication options.
Qué hacen
- Develops and commercializes pharmaceutical products.
- Focuses on abuse-deterrent drug delivery technologies.
- Offers Oxaydo tablets for pain management.
- Provides Nexafed products for nasal decongestion.
- Engages in research and development of new formulations.
- Collaborates with other pharmaceutical companies for product development and commercialization.
Modelo de Negocio
- Develops and patents proprietary drug delivery technologies.
- Manufactures and sells pharmaceutical products through partnerships and direct sales.
- Generates revenue through product sales and licensing agreements.
- Invests in research and development to expand its product pipeline.
Contexto de la Industria
Acura Pharmaceuticals, Inc. operates within the specialty pharmaceutical industry, which is characterized by a focus on developing niche products and innovative drug delivery systems. The industry is driven by the need for safer and more effective medications, particularly in areas such as pain management and abuse deterrence. The competitive landscape includes both large pharmaceutical companies and smaller, specialized firms. Acura's focus on abuse-deterrent formulations positions it within a growing segment of the market, driven by increasing concerns about opioid abuse and regulatory pressures to develop safer alternatives. The global pharmaceutical market is projected to reach trillions of dollars by 2026, with specialty pharmaceuticals representing a significant portion of this growth.
Clientes Clave
- Patients suffering from acute and chronic pain.
- Individuals seeking relief from nasal congestion.
- Pharmaceutical companies seeking to incorporate abuse-deterrent technologies into their products.
- Distributors and wholesalers of pharmaceutical products.
Finanzas
Gráfico e información
Precio de la acción de Acura Pharmaceuticals, Inc. (ACUR): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Highs On Tuesday
· 5 nov 2019
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ACUR.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ACUR.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ACUR en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Robert Jones
CEO
Robert Jones serves as the CEO of Acura Pharmaceuticals, Inc., leading a team of 9 employees. Information regarding his detailed career history, education, and previous roles is not available in the provided source data. Therefore, a comprehensive background summary cannot be provided at this time.
Historial: Due to the limited information available in the provided source data, a detailed track record of Robert Jones' key achievements, strategic decisions, and company milestones under his leadership cannot be accurately assessed.
Información del mercado OTC de ACUR
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acura Pharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity, price volatility, and lack of transparency compared to exchange-listed stocks.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity due to low trading volume on the OTC market.
- Higher price volatility compared to exchange-listed stocks.
- Potential for limited or inconsistent financial disclosures.
- Increased risk of fraud or manipulation due to less regulatory oversight.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the company's capital structure and debt levels.
- Determine the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been incorporated since 1935, indicating a long operating history.
- Acura Pharmaceuticals, Inc. has existing commercialized products (Oxaydo and Nexafed).
- The company has collaboration and license agreements with other pharmaceutical companies.
- Acura Pharmaceuticals, Inc. is focused on developing abuse-deterrent formulations, addressing a significant public health concern.
- The company has a team of employees, suggesting ongoing operations.
Lo Que los Inversores Preguntan Sobre Acura Pharmaceuticals, Inc. (ACUR)
¿Cuáles son los factores clave para evaluar ACUR?
Acura Pharmaceuticals, Inc. (ACUR) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Proprietary abuse-deterrent drug delivery technologies.. Riesgo principal a monitorear: Potential: Competition from larger pharmaceutical companies with greater resources.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ACUR?
ACUR actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ACUR?
Los precios de ACUR se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ACUR?
La cobertura de analistas para ACUR incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ACUR?
Las categorías de riesgo para ACUR incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from larger pharmaceutical companies with greater resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ACUR?
La relación P/E para ACUR compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ACUR sobrevalorada o infravalorada?
Determinar si Acura Pharmaceuticals, Inc. (ACUR) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ACUR?
Acura Pharmaceuticals, Inc. (ACUR) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data as of 2026-03-16.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights in the future.